Search

Your search keyword '"Chen, Shinn-Cherng"' showing total 631 results
Start Over Author "Chen, Shinn-Cherng"
631 results on '"Chen, Shinn-Cherng"'

102. Improvement of hyperuricemia in chronic hepatitis C patients receiving directly acting antiviral agents

Author

Jang, Tyng‐Yuan, primary, Huang, Ching‐I, additional, Yeh, Ming‐Lun, additional, Liang, Po‐Cheng, additional, Tsai, Pei‐Chien, additional, Lin, Yi‐Hung, additional, Hsieh, Ming‐Yen, additional, Hou, Nai‐Jen, additional, Lin, Zu‐Yau, additional, Chen, Shinn‐Cherng, additional, Huang, Jee‐Fu, additional, Dai, Chia‐Yen, additional, Huang, Chung‐Feng, additional, Chuang, Wan‐Long, additional, and Yu, Ming‐Lung, additional

Published
2019
Full Text
View/download PDF

103. Ribavirin facilitates early viral kinetics in chronic hepatitis C patients receiving daclatasvir/asunaprevir

Author

Huang, Chung‐Feng, primary, Yeh, Ming‐Lun, additional, Huang, Ching‐I, additional, Liang, Po‐Cheng, additional, Lin, Yi‐Hung, additional, Hsieh, Ming‐Yen, additional, Chen, Kuan‐Yu, additional, Ko, Yu‐Min, additional, Lin, Zu‐Yau, additional, Chen, Shinn‐Cherng, additional, Huang, Jee‐Fu, additional, Dai, Chia‐Yen, additional, Chuang, Wan‐Long, additional, and Yu, Ming‐Lung, additional

Published
2019
Full Text
View/download PDF

104. Equal treatment efficacy of direct-acting antivirals in patients with chronic hepatitis C and hepatocellular carcinoma? A prospective cohort study

Author

Huang, Chung-Feng, primary, Yeh, Ming-Lun, additional, Huang, Ching-I, additional, Liang, Po-Cheng, additional, Lin, Yi-Hung, additional, Hsieh, Ming-Yen, additional, Wei, Yu-Ju, additional, Lin, Zu-Yau, additional, Chen, Shinn-Cherng, additional, Huang, Jee-Fu, additional, Dai, Chia-Yen, additional, Chuang, Wan-Long, additional, and Yu, Ming-Lung, additional

Published
2019
Full Text
View/download PDF

105. The acceptability of serum sample storage for hepatitis C viral load analysis in chronic hepatitis C patients

Author

Huang, Ying‐Chou, primary, Liu, Shu‐Fen, additional, Liu, Hung‐Yin, additional, Huang, Chung‐Feng, additional, Yeh, Ming‐Lun, additional, Dai, Chia‐Yen, additional, Tsai, Pei‐Chien, additional, Chen, Shinn‐Cherng, additional, Yu, Ming‐Lung, additional, Chuang, Wan‐Long, additional, and Huang, Jee‐Fu, additional

Published
2019
Full Text
View/download PDF

106. Elevated interleukin-4 levels predicted advanced fibrosis in chronic hepatitis C

Author

Batsaikhan, Batbold, primary, Lu, Ming-Ying, additional, Yeh, Ming-Lun, additional, Huang, Ching-I, additional, Huang, Chung-Feng, additional, Lin, Zu-Yau, additional, Chen, Shinn-Cherng, additional, Huang, Jee-Fu, additional, Hsieh, Ping-Hsin, additional, Chuang, Wan-Long, additional, Lee, Jin-Ching, additional, Yu, Ming-Lung, additional, and Dai, Chia-Yen, additional

Published
2019
Full Text
View/download PDF

108. Elevated serum ferritin level associated with hepatic steatosis and fibrosis in hepatitis C virus–infected patients

Author

Batsaikhan, Batbold, primary, Gantumur, Gantsetseg, additional, Huang, Ching-I, additional, Yeh, Ming-Lun, additional, Huang, Chung-Feng, additional, Lin, Zu-Yau, additional, Chen, Shinn-Cherng, additional, Huang, Jee-Fu, additional, Yu, Ming-Lung, additional, Chuang, Wan-Long, additional, Lee, Jin-Ching, additional, and Dai, Chia-Yen, additional

Published
2019
Full Text
View/download PDF

110. Pretreatment Hepatitis B Viral Load Predicts Long-Term Hepatitis B Response After Anti-Hepatitis C Therapy in Hepatitis B/C Dual-Infected Patients

Author

Yeh, Ming-Lun, primary, Huang, Ching-I, additional, Huang, Chung-Feng, additional, Hsieh, Meng-Hsuan, additional, Liu, Ta-Wei, additional, Lin, Yi-Hung, additional, Liang, Po-Cheng, additional, Hsieh, Ming-Yen, additional, Lin, Zu-Yau, additional, Chen, Shinn-Cherng, additional, Huang, Jee-Fu, additional, Kuo, Po-Lin, additional, Dai, Chia-Yen, additional, Yu, Ming-Lung, additional, and Chuang, Wan-Long, additional

Published
2018
Full Text
View/download PDF

116. High versus standard doses interferon-alpha in the treatment of naïve chronic hepatitis C patients in Taiwan: a 10-year cohort study

Author

Tsai Jung-Fa, Wang Liang-Yen, Hsieh Ming-Yuh, Lin Zu-Yau, Hsieh Ming-Yen, Lee Li-Po, Chen Shinn-Cherng, Dai Chia-Yen, Yu Ming-Lung, Chang Wen-Yu, and Chuang Wan-Long

Subjects
Infectious and parasitic diseases, RC109-216
Abstract

Abstract Background Interferon-alpha monotherapy is effective in less than one-third patients with chronic hepatitis C. The dose-effect, tolerability and durability of interferon-alpha treatment and its long-term effect on the prevention of cirrhosis and hepatocellular carcinoma in naïve Taiwanese patients with chronic hepatitis C have not been well investigated. We conducted the present cohort study treated with high and standard interferon-alpha to illustrate the issues. Methods We performed a long-term virologic and histological follow-up of 214 chronic hepatitis C patients treated with interferon-alpha, 3 million units (3-MU, n = 80) or 6-MU (n = 134) thrice weekly for 24 weeks, in Taiwan between 1992 and 2001. Results There was no difference in the incidence of discontinuation between 3-MU and 6-MU groups (4/80, 5.0% versus 10/134. 7.5%). The 6-MU group had similar incidence of adverse events with the 3-MU group, except that 6-MU group had significantly higher incidence of psychological manifestations, mainly presented as irritability. The rates of sustained virological response (SVR) were significantly higher in 6-MU regimen (37.1%) than in 3-MU regimen (23.7%, p < 0.05) in per protocol analysis. Based on multivariate analysis, baseline viral load was strongly associated with SVR, followed by hepatitis C virus genotype, interferon-alpha regimen, and liver fibrosis. A histological improvement in necroinflammatory activity, but not in fibrosis was observed in the follow-up biopsy performed 0.5–5.5 years (mean: 1.9 years, n = 51) after end-of-treatment. Among patients without SVR, there was more activity improvement in 6-MU group. The durability of SVR was 100% (18/18) and 97.8% (45/46) for 3-MU and 6-MU group, respectively, in a mean follow-up period of 6.81 years (5.25–9.18 years). For 163 baseline non-cirrhotic patients, 9 of 84 (10.7%) non-responders and 3 of 79 (3.8%) sustained responders progressed to cirrhosis during a mean follow-up period of 5.52 and 5.74 years, respectively (p = 0.067, Kaplan-Meier survival analysis, log-rank test). For all 200 patients, hepatocellular carcinoma was detected in 12 of 113 (10.6%) non-responders and one of 87 (1.1%) sustained responders during a mean follow-up period of 5.67 and 5.73 years, respectively (p < 0.01, Kaplan-Meier survival analysis, log-rank test). Conclusion We confirm the dose effect of interferon-alpha in chronic hepatitis C. Six-MU regimen had better efficacy than 3-MU regimen in virologic and histological responses. Both regimens had good tolerability and durability in Taiwan. Sustained response could reduce the incidence of cirrhotic change and hepatocarcinogenesis.

Published
2005
Full Text
View/download PDF

117. Early Fibrosis but Late Tumor Stage and Worse Outcomes in Hepatocellular Carcinoma Patients Without Hepatitis B or Hepatitis C.

Author

Hsu, Po-Yao, Hsu, Cheng-Ting, Yeh, Ming-Lun, Huang, Chung-Feng, Huang, Ching-I, Liang, Po-Cheng, Lin, Yi-Hung, Hsieh, Ming-Yen, Wei, Yu-Ju, Hsieh, Meng-Hsuan, Dai, Chia-Yen, Lin, Zu-Yau, Chen, Shinn-Cherng, Huang, Jee-Fu, Yu, Ming-Lung, and Chuang, Wan-Long

Subjects
HYPERTENSION epidemiology, THERAPEUTIC use of antineoplastic agents, OBESITY, SURVIVAL, RESEARCH, LIVER tumors, CHRONIC hepatitis C, RESEARCH methodology, CIRRHOSIS of the liver, DIABETES, PROGNOSIS, CATHETER ablation, CHEMOEMBOLIZATION, EVALUATION research, MEDICAL cooperation, SERUM albumin, TUMOR classification, SEVERITY of illness index, COMPARATIVE studies, PLATELET count, DISEASE prevalence, RESEARCH funding, RADIOTHERAPY, LIVER transplantation, HEPATOCELLULAR carcinoma, ASPARTATE aminotransferase, PROPORTIONAL hazards models, ALANINE aminotransferase, CHRONIC hepatitis B, COMORBIDITY, HEPATECTOMY, DISEASE complications
Abstract

Background and Aims: The features of non-viral, nonalcohol hepatocellular carcinoma (NBNC-HCC) remain elusive. The aim of this study was to investigate this clinical characteristics and overall survival of NBNC-HCC compared to hepatitis B- (HBV-HCC) and hepatitis C-related (HCV-HCC) HCC.Methods: We analyzed the etiologies, fibrosis stages, clinical data, and outcomes of newly diagnosed patients with HCC.Results: A total of 1777 HCC patients were recruited, including 332 patients with NBNC-HCC, 682 patients with HBV-HCC, 680 patients with HCV-HCC, and 83 patients with HBV/HCV HCC. Patients with NBNC-HCC were older (69.9 ± 11.9 years). Patients with NBNC-HCC exhibited a higher prevalence of diabetes (43.9%) compared to the HBV-HCC (27.1%, p < 0.05) and HCV-HCC (30.2%, p < 0.05) groups. Compared to patients from the viral-related HCC groups, patients with NBNC-HCC exhibited a significantly lower fibrosis stage. NBNC-HCC patients exhibited a higher proportion of Barcelona Clinic Liver Cancer (BCLC) classification stage C and stage D compared to patients from the HBV-HCC and HCV-HCC groups. With a mean of 2.33 ± 2.31 years of follow-up, the median survival of patients with NBNC-HCC was 1.75 (95% CI 1.33-2.17) years, which was significantly lower than that of patients with HBV-HCC (p = 0.041) and HCV-HCC (p < 0.001).Conclusions: Patients with NBNC-HCC have a higher risk of diabetes than patients with HCC of viral etiologies. Although patients with NBNC-HCC exhibited a milder fibrosis stage, their more advanced HCC stages and worse overall survival should be taken into consideration in clinical care. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

118. Improvement of hyperuricemia in chronic hepatitis C patients receiving directly acting antiviral agents.

Author

Jang, Tyng‐Yuan, Huang, Ching‐I, Yeh, Ming‐Lun, Liang, Po‐Cheng, Tsai, Pei‐Chien, Lin, Yi‐Hung, Hsieh, Ming‐Yen, Hou, Nai‐Jen, Lin, Zu‐Yau, Chen, Shinn‐Cherng, Huang, Jee‐Fu, Dai, Chia‐Yen, Huang, Chung‐Feng, Chuang, Wan‐Long, and Yu, Ming‐Lung

Subjects
CHRONIC hepatitis C, ANTIVIRAL agents, HEPATITIS C virus, GLOMERULAR filtration rate, URIC acid
Abstract

Background and Aim: Hepatitis C virus eradication via the use of antivirals ameliorates metabolic profiles. The changes in serum uric acid (SUA) levels in chronic hepatitis C patients who receive antivirals are not well understood. We aimed to address this issue by comparing the SUA changes before and after the achievement of a sustained virological response (which is defined as hepatitis C virus RNA seronegativity at 12 weeks after the end of treatment). Methods: Two hundred and thirteen sustained virological response patients who were treated by directly acting antivirals were consecutively enrolled. Pretreatment and post‐treatment SUA levels were compared. Hyperuricemia was defined as a uric acid level > 7.0 mg/dL in men and > 6.0 mg/dL in women. Results: The SUA levels significantly decreased after treatment, as compared to the pretreatment levels (5.6 ± 1.5 vs 6.0 ± 1.7 mg/dL, respectively; P < 0.001). The proportion of hyperuricemia incidences significantly decreased after treatment (25.8% vs 35.7%, respectively; P = 0.001). The improvement was only observed in patients with a fibrosis‐4 index (FIB‐4) < 6.5 (25.7% vs 37.1%, P = 0.001) but not in those patients with a FIB‐4 ≧ 6.5 (26.3% vs 28.9%, P = 1.00). A multivariate analysis revealed that the factor that was associated with significantly decreased SUA levels was FIB‐4 < 6.5 (odds ratio [OR]/95% confidence interval [CI]: 3.22/1.04–9.95, P = 0.04) and estimated glomerular filtration rate < 60 mL/min/1.73 m2 (OR/CI: 4.34/1.94–9.73, P < 0.001). There existed a trend of a higher proportion of patients with significant SUA improvement along with the decrement of FIB‐4 (29.7%, 25%, and 10.5% in patients with FIB‐4 < 3.25, 3.25–6.5, and > 6.5, respectively; trend P = 0.03). Conclusions: SUA levels were significantly decreased in chronic hepatitis C patients after viral eradication. The improvement was particularly enhanced in patients with mild liver disease. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

119. Ribavirin facilitates early viral kinetics in chronic hepatitis C patients receiving daclatasvir/asunaprevir.

Author

Huang, Chung‐Feng, Yeh, Ming‐Lun, Huang, Ching‐I, Liang, Po‐Cheng, Lin, Yi‐Hung, Hsieh, Ming‐Yen, Chen, Kuan‐Yu, Ko, Yu‐Min, Lin, Zu‐Yau, Chen, Shinn‐Cherng, Huang, Jee‐Fu, Dai, Chia‐Yen, Chuang, Wan‐Long, and Yu, Ming‐Lung

Subjects
CHRONIC hepatitis C, RIBAVIRIN, LOGISTIC regression analysis, HEPATITIS C virus
Abstract

Background and Aim: Ribavirin (RBV) remains crucial in difficult‐to‐cure chronic hepatitis C patients receiving directly acting antivirals (DAAs). The current study aimed to address whether RBV enhanced early viral kinetics in patients with DAAs. Methods: Hepatitis C virus (HCV) genotype‐1b patients were allocated to daclatasvir/asunaprevir +weight‐based RBV (1000–1200 mg/day) for 12–24 weeks. HCV RNA levels were compared at day 1, week 1, week 2, and week 4 of treatment. Results: The sustained virological response rate was 100% (67/67) and 96.7% (59/61) in the RBV and non‐RBV group, respectively. The HCV RNA levels at treatment week 2 (W2) were significantly lower in the RBV group than in the non‐RBV group (0.42 ± 0.81 log IU/mL vs 0.79 ± 1.03 log IU/mL, P = 0.04). Among the intermediate responders who remained to have detectable RNA after W1 of treatment, patients with RBV had a significantly higher rate of undetectable HCV RNA (71.4% vs 36.0%, P = 0.003) and lower HCV RNA level at W2 (0.55 ± 0.89 log IU/mL vs 1.32 ± 1.04 log IU/mL, P = 0.001). A more significant magnitude of HCV RNA reduction was also noted from baseline to day 1 (3.15 ± 0.38 log IU/mL vs 2.80 ± 0.70 log IU/mL, P = 0.009) and W1 to W2 (1.40 ± 0.65 log IU/mL vs 0.88 ± 0.78 log IU/mL, P = 0.007) in the RBV group compared to the non‐RBV group among the intermediate responders. Logistic regression analysis revealed that adding RBV independently predicted undetectable HCV RNA at W2 (odds ratio/confidence interval: 4.74/1.54–14.57, P = 0.007) in the intermediate responders. Conclusions: Adding RBV to DAAs improved early viral kinetic, in particular, for intermediate responders. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

120. Association of serial serum major histocompatibility complex class I chain‐related A measurements with hepatocellular carcinoma in chronic hepatitis C patients after viral eradication

Author

Huang, Chung‐Feng, primary, Wang, Shu‐Chi, additional, Yeh, Ming‐Lun, additional, Huang, Ching‐I, additional, Tsai, Pei‐Chien, additional, Lin, Zu‐Yau, additional, Chen, Shinn‐Cherng, additional, Dai, Chia‐Yen, additional, Huang, Jee‐Fu, additional, Chuang, Wan‐Long, additional, Chen, Angela, additional, and Yu, Ming‐Lung, additional

Published
2018
Full Text
View/download PDF

121. Paritaprevir/ritonavir/ombitasvir plus dasabuvir with ribavirin for treatment of recurrent chronic hepatitis C genotype 1 infection after liver transplantation: Real-world experience

Author

Yu, Ming-Lung, primary, Chen, Yao-Li, additional, Huang, Chung-Feng, additional, Lin, Kuo-Hua, additional, Yeh, Ming-Lun, additional, Huang, Ching-I., additional, Hsieh, Meng-Hsuan, additional, Lin, Zu-Yau, additional, Chen, Shinn-Cherng, additional, Huang, Jee-Fu, additional, Dai, Chia-Yen, additional, and Chuang, Wan-Long, additional

Published
2018
Full Text
View/download PDF

122. Management consensus guideline for hepatocellular carcinoma: 2016 updated by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan

Author

Lu, Sheng-Nan, primary, Wang, Jing-Houng, additional, Su, Chien-Wei, additional, Wang, Tsang-En, additional, Dai, Chia-Yen, additional, Chen, Chien-Hung, additional, Chen, Ran-Chou, additional, Yang, Sien-Sing, additional, Hung, Chien-Fu, additional, Huang, Shiu-Feng, additional, Liao, Li-Ying, additional, Lu, Sheng-Nan, additional, Huo, The-Ia, additional, Wu, Cheng-Chung, additional, Lee, Po-Huang, additional, Ting, Chin-Tsung, additional, Lee, Wei-Chen, additional, Chau, Gar-Yang, additional, Wang, Chih-Chi, additional, Lee, King-The, additional, Huang, Yi-Hsiang, additional, Ho, Ming-Chih, additional, Lin, Shi-Ming, additional, Huang, Guan-Tarn, additional, Chen, Kuan-Yang, additional, Lin, Xi-Zhang, additional, Hwang, Jen-I., additional, Chiou, Yi-You, additional, Wang, Chung-Kwe, additional, Hu, Jui-Ting, additional, Chen, Shinn-Cherng, additional, Liang, Po-Chin, additional, Lee, Rheun-Chuan, additional, Wu, Ding-Kwo, additional, Lin, Cheng-Yao, additional, Lin, Chen-Chun, additional, Cheng, Ann-Lii, additional, Hsu, Chiun, additional, Chao, Yee, additional, Chen, Li-Tzong, additional, Wang, Po-Ming, additional, Hong, Ji-Hong, additional, Hsu, Hsuan-Chih, additional, Chen, Shang-Wen, additional, Leung, Stephen Wan, additional, Cheng, Jason Chia-Hsien, additional, Wu, Jaw-Ching, additional, Wu, Chun-Ying, additional, Hsu, Yao-Chun, additional, Hsu, Chao-Wei, additional, Ni, Yen-Hsuan, additional, and Lin, Chih-Lin, additional

Published
2018
Full Text
View/download PDF

123. The effect of antiviral therapy on serum lipid profiles in chronic hepatitis C

Author

Batsaikhan, Batbold, primary, Huang, Ching-I, additional, Yeh, Ming-Lun, additional, Huang, Chung-Feng, additional, Hou, Nei-Jen, additional, Lin, Zu-Yau, additional, Chen, Shinn-Cherng, additional, Huang, Jee-Fu, additional, Yu, Ming-Lung, additional, Chuang, Wan-Long, additional, Lee, Jin-Ching, additional, and Dai, Chia-Yen, additional

Published
2018
Full Text
View/download PDF

125. Post-treatment alpha fetoprotein and platelets predict hepatocellular carcinoma development in dual-infected hepatitis B and C patients after eradication of hepatitis C

Author

Yeh, Ming-Lun, primary, Huang, Ching-I, additional, Huang, Chung-Feng, additional, Hsieh, Meng-Hsuan, additional, Hsieh, Ming-Yen, additional, Lin, Zu-Yau, additional, Chen, Shinn-Cherng, additional, Huang, Jee-Fu, additional, Kuo, Po-Lin, additional, Kuo, Hsing-Tao, additional, Dai, Chia-Yen, additional, Yu, Ming-Lung, additional, and Chuang, Wan-Long, additional

Published
2018
Full Text
View/download PDF

126. Impact of Ribavirin on Early Viral Kinetics in Chronic Hepatitis C Patients Receiving Directly Acting Antivirals

Author

Huang, Chung-Feng, primary, Yeh, Ming-Lun, additional, Huang, Ching-I, additional, Liang, Po-Cheng, additional, Lin, Yi-Hung, additional, Hsieh, Ming-Yen, additional, Lin, Zu-Yau, additional, Chen, Shinn-Cherng, additional, Huang, Jee-Fu, additional, Dai, Chia-Yen, additional, Chuang, Wan-Long, additional, and Yu, Ming-Lung, additional

Published
2018
Full Text
View/download PDF

127. Identification of treatment-experienced hepatitis C patients with poor cost-effectiveness of pegylated interferon plus ribavirin from a real-world cohort

Author

Liu, Ta-Wei, primary, Tsai, Pei-Chien, additional, Huang, Ching-I, additional, Tsai, Yi-Shan, additional, Wang, Shu-Chi, additional, Ko, Yu-Min, additional, Lin, Ching-Chih, additional, Chen, Kuan-Yu, additional, Liang, Po-Cheng, additional, Lin, Yi-Hung, additional, Hsieh, Ming-Yen, additional, Hou, Nai-Jen, additional, Huang, Chung-Feng, additional, Yeh, Ming-Lun, additional, Lin, Zu-Yau, additional, Chen, Shinn-Cherng, additional, Dai, Chia-Yen, additional, Chuang, Wan-Long, additional, Huang, Jee-Fu, additional, and Yu, Ming-Lung, additional

Published
2018
Full Text
View/download PDF

128. The treatment outcome and impact on blood transfusion demand of Peg-interferon/ribavirin in thalassemic patients with chronic hepatitis C

Author

Liang, Po-Cheng, primary, Lin, Pei-Chin, additional, Huang, Ching-I., additional, Huang, Chung-Feng, additional, Yeh, Ming-Lun, additional, Zeng, Yu-Sheng, additional, Hsu, Wan-Yi, additional, Hsieh, Ming-Yen, additional, Lin, Zu-Yau, additional, Chen, Shinn-Cherng, additional, Huang, Jee-Fu, additional, Dai, Chia-Yen, additional, Chuang, Wan-Long, additional, Chiou, Shyh-Shin, additional, and Yu, Ming-Lung, additional

Published
2018
Full Text
View/download PDF

130. Serum Wisteria floribunda agglutinin‐positive Mac‐2‐binding protein expression predicts disease severity in chronic hepatitis C patients

Author

Huang, Ching‐I, primary, Huang, Chung‐Feng, additional, Yeh, Ming‐Lun, additional, Lin, Yi‐Hung, additional, Liang, Po‐Cheng, additional, Hsieh, Meng‐Hsuan, additional, Dai, Chia‐Yen, additional, Hsieh, Ming‐Yen, additional, Lin, Zu‐Yau, additional, Chen, Shinn‐Cherng, additional, Huang, Jee‐Fu, additional, Yu, Ming‐Lung, additional, and Chuang, Wan‐Long, additional

Published
2017
Full Text
View/download PDF

131. Seroprevalence and clinical characteristics of viral hepatitis in transfusion-dependent thalassemia and hemophilia patients

Author

Jang, Tyng-Yuan, primary, Lin, Pei-Chin, additional, Huang, Ching-I, additional, Liao, Yu-Mei, additional, Yeh, Ming-Lun, additional, Zeng, Yu-Sheng, additional, Liang, Po-Cheng, additional, Hsu, Wan-Yi, additional, Tsai, Shih-Pien, additional, Lin, Zu-Yau, additional, Chen, Shinn-Cherng, additional, Huang, Jee-Fu, additional, Dai, Chia-Yen, additional, Huang, Chung-Feng, additional, Chiou, Shyh-Shin, additional, Chuang, Wan-Long, additional, and Yu, Ming-Lung, additional

Published
2017
Full Text
View/download PDF

133. Identification of groups with poor cost-effectiveness of peginterferon plus ribavirin for naïve hepatitis C patients with a real-world cohort and database

Author

Tsai, Pei-Chien, primary, Liu, Ta-Wei, additional, Tsai, Yi-Shan, additional, Ko, Yu-Min, additional, Chen, Kuan-Yu, additional, Lin, Ching-Chih, additional, Huang, Ching-I, additional, Liang, Po-Cheng, additional, Lin, Yi-Hung, additional, Hsieh, Ming-Yen, additional, Hou, Nai-Jen, additional, Huang, Chung-Feng, additional, Yeh, Ming-Lun, additional, Lin, Zu-Yau, additional, Chen, Shinn-Cherng, additional, Dai, Chia-Yen, additional, Chuang, Wan-Long, additional, Huang, Jee-Fu, additional, and Yu, Ming-Lung, additional

Published
2017
Full Text
View/download PDF

134. Time-Degenerative Factors and the Risk of Hepatocellular Carcinoma after Antiviral Therapy among Hepatitis C Virus Patients: A Model for Prioritization of Treatment

Author

Yu, Ming-Lung, primary, Huang, Chung-Feng, additional, Yeh, Ming-Lun, additional, Tsai, Pei-Chien, additional, Huang, Ching-I., additional, Hsieh, Meng-Hsuan, additional, Hsieh, Ming-Yen, additional, Lin, Zu-Yau, additional, Chen, Shinn-Cherng, additional, Huang, Jee-Fu, additional, Dai, Chia-Yen, additional, and Chuang, Wan-Long, additional

Published
2017
Full Text
View/download PDF

135. Disease severity and erythropoiesis in chronic hepatitis C

Author

Huang, Chung-Feng, primary, Huang, Ching-I, additional, Yeh, Ming-Lun, additional, Hou, Chen, additional, Hou, Nai-Jen, additional, Hsieh, Ming-Yen, additional, Huang, Jee-Fu, additional, Chen, Shinn-Cherng, additional, Lin, Zu-Yau, additional, Dai, Chia-Yen, additional, Chuang, Wan-Long, additional, and Yu, Ming-Lung, additional

Published
2017
Full Text
View/download PDF

136. Diversity of the association of serum levels and genetic variants of MHC class I polypeptide-related chain A with liver fibrosis in chronic hepatitis C

Author

Huang, Chung-Feng, primary, Huang, Ching-I, additional, Yeh, Ming-Lun, additional, Wang, Shu-Chi, additional, Chen, Kuan-Yu, additional, Ko, Yu-Min, additional, Lin, Ching-Chih, additional, Tsai, Yi-Shan, additional, Tsai, Pei-Chien, additional, Lin, Zu-Yau, additional, Chen, Shinn-Cherng, additional, Dai, Chia-Yen, additional, Huang, Jee-Fu, additional, Chuang, Wan-Long, additional, and Yu, Ming-Lung, additional

Published
2017
Full Text
View/download PDF

137. Corrigendum to “Genetics Variants and Serum Levels of MHC Class I Chain-related A in Predicting Hepatocellular Carcinoma Development in Chronic Hepatitis C Patients Post Antiviral Treatment” [EBioMedicine 15 (2017) 81–89]

Author

Huang, Chung-Feng, primary, Huang, Ching-I, additional, Yeh, Ming-Lun, additional, Wang, Shu-Chi, additional, Chen, Kuan-Yu, additional, Ko, Yu-Min, additional, Lin, Ching-Chih, additional, Tsai, Yi-Shan, additional, Tsai, Pei-Chien, additional, Lin, Zu-Yau, additional, Chen, Shinn-Cherng, additional, Dai, Chia-Yen, additional, Huang, Jee-Fu, additional, Chuang, Wan-Long, additional, and Yu, Ming-Lung, additional

Published
2017
Full Text
View/download PDF

138. Risk of hepatitis C virus related hepatocellular carcinoma between subjects with spontaneous and treatment-induced viral clearance

Author

Huang, Chung-Feng, primary, Yeh, Ming-Lun, additional, Huang, Ching-I, additional, Lin, Yu-Ju, additional, Tsai, Pei-Chien, additional, Lin, Zu-Yau, additional, Chan, Soa-Yu, additional, Chen, Shinn-Cherng, additional, Yang, Hwai-I, additional, Huang, Jee-Fu, additional, Lu, Sheng-Nan, additional, Dai, Chia-Yen, additional, Jen, Chin-Lan, additional, Yuan, Yong, additional, L’Italien, Gilbert, additional, Wang, Li-Yu, additional, Lee, Mei-Hsuan, additional, Yu, Ming-Lung, additional, Chuang, Wan-Long, additional, and Chen, Chien-Jen, additional

Published
2017
Full Text
View/download PDF

139. Genetics Variants and Serum Levels of MHC Class I Chain-related A in Predicting Hepatocellular Carcinoma Development in Chronic Hepatitis C Patients Post Antiviral Treatment

Author

Huang, Chung-Feng, primary, Huang, Cing-Yi, additional, Yeh, Ming-Lun, additional, Wang, Shu-Chi, additional, Chen, Kuan-Yu, additional, Ko, Yu-Min, additional, Lin, Ching-Chih, additional, Tsai, Yi-Shan, additional, Tsai, Pei-Chien, additional, Lin, Zu-Yau, additional, Chen, Shinn-Cherng, additional, Dai, Chia-Yen, additional, Huang, Jee-Fu, additional, Chuang, Wan-Long, additional, and Yu, Ming-Lung, additional

Published
2017
Full Text
View/download PDF

141. HATT: a phase IV, single-arm, open-label study of sorafenib in Taiwanese patients with advanced hepatocellular carcinoma

Author

Lin, Shi-Ming, primary, Lu, Sheng-Nan, additional, Chen, Ping-Tsung, additional, Jeng, Long-Bin, additional, Chen, Shinn-Cherng, additional, Hu, Chi-Tan, additional, Yang, Sien-Sing, additional, Le Berre, Marie-Aude, additional, Liu, Xuan, additional, Mitchell, David Y., additional, Prins, Klaas, additional, Grevel, Joachim, additional, Peña, Carol A. E., additional, and Meinhardt, Gerold, additional

Published
2016
Full Text
View/download PDF

142. A real‐world impact of cost‐effectiveness of pegylated interferon/ribavarin regimens on treatment‐naïve chronic hepatitis C patients in Taiwan

Author

Tsai, Pei‐Chien, primary, Liu, Ta‐Wei, additional, Hsieh, Meng‐Hsuan, additional, Yeh, Ming‐Lun, additional, Liang, Po‐Cheng, additional, Lin, Yi‐Hung, additional, Huang, Ching‐I, additional, Huang, Chung‐Feng, additional, Hsieh, Ming‐Yen, additional, Hou, Nai‐Jen, additional, Lin, Zu‐Yau, additional, Chen, Shinn‐Cherng, additional, Huang, Jee‐Fu, additional, Dai, Chia‐Yen, additional, Chuang, Wan‐Long, additional, and Yu, Ming‐Lung, additional

Published
2016
Full Text
View/download PDF

143. Huge Gap Between Clinical Efficacy and Community Effectiveness in the Treatment of Chronic Hepatitis C

Author

Yu, Ming-Lung, Yeh, Ming-Lun, Tsai, Pei-Chien, Huang, Ching-I., Huang, Jee-Fu, Huang, Chung-Feng, Hsieh, Meng-Hsuan, Liang, Po-Cheng, Lin, Yi-Hung, Hsieh, Ming-Yen, Lin, Wen-Yi, Hou, Nai-Jen, Lin, Zu-Yau, Chen, Shinn-Cherng, Dai, Chia-Yen, Chuang, Wan-Long, and Chang, Wen-Yu

Subjects
Adult, Male, Health Knowledge, Attitudes, Practice, Taiwan, Observational Study, Interferon-alpha, Hepatitis C, Chronic, Interferon alpha-2, Middle Aged, Antiviral Agents, Article, Health Services Accessibility, Recombinant Proteins, Medication Adherence, Polyethylene Glycols, Ribavirin, ComputingMethodologies_DOCUMENTANDTEXTPROCESSING, Prevalence, Humans, Female, Prospective Studies, Aged
Abstract

Supplemental Digital Content is available in the text, Peginterferon/ribavirin provides a substantially high treatment efficacy for chronic hepatitis C virus (HCV) infections in Asians. Whether the clinical efficacy can be translated to community effectiveness remains unclear. The disease awareness, treatment accessibility, recommendations, acceptance, and barriers to anti-HCV treatment were explored to clarify the issue with a 3-step nationwide investigation in Taiwan. A crude HCV-infected population was estimated using databases from 3 large-scale surveillance studies and age-/geographic-specific population database. HCV awareness and accessibility were investigated at the patient level in 58,129 residents. The recommendations/acceptances and barriers to treatment at the provider level were evaluated using a prospective, nationwide approach to 89 gastroenterologists/hepatologists. The estimated 10-year interval age-adjusted anti-HCV-seropositive population is 745,109 (3.28%), with an anticipated HCV-viremic population of 554,361. Of anti-HCV-seropositive subjects, 36.2% had disease awareness. Among those with awareness, 39.6% had accessibility. The recommendation/acceptance rate of antiviral therapy was 70.6%. The treatment rate was 10.1% and 13.7% for the anti-HCV-seropositive and HCV-viremic population, respectively. With an anticipated treatment success rate of 80% in Taiwan, 8.1% of the anti-HCV-seropositive and 10.9% of the HCV-viremic population achieved successful treatment. The major treatment barriers were fear of adverse effects (37%), major disorders (17.6%), ineligibility for insurance reimbursement (17.6%), and lack of therapy awareness (11.3%). Despite the high rates of treatment response and nationwide coverage of insurance reimbursement, there remains a large gap between clinical efficacy and community effectiveness in anti-HCV treatment in Taiwan. Increasing disease awareness/treatment accessibility and introducing new therapeutic strategies with high tolerability are warranted.

Published
2015

144. Pretreatment Hepatitis B Viral Load Predicts Long-Term Hepatitis B Response After Anti-Hepatitis C Therapy in Hepatitis B/C Dual-Infected Patients.

Author

Yeh, Ming-Lun, Huang, Ching-I, Huang, Chung-Feng, Hsieh, Meng-Hsuan, Liu, Ta-Wei, Lin, Yi-Hung, Liang, Po-Cheng, Hsieh, Ming-Yen, Lin, Zu-Yau, Chen, Shinn-Cherng, Huang, Jee-Fu, Kuo, Po-Lin, Dai, Chia-Yen, Yu, Ming-Lung, and Chuang, Wan-Long

Subjects
VIRAL hepatitis, HEPATITIS B, HEPATITIS associated antigen, HEPATITIS C, VIRAL load, ANTIVIRAL agents, COMPARATIVE studies, HEPATITIS viruses, RESEARCH methodology, MEDICAL cooperation, RESEARCH, VIRAL antigens, EVALUATION research, ALANINE aminotransferase, TREATMENT effectiveness, PREDICTIVE tests, MIXED infections, DISEASE complications
Abstract

Background: We aimed to investigate the long-term outcomes in hepatitis B (HBV)/hepatitis C virus (HCV) dual-infected patients after anti-HCV therapy.Methods: A total of 192 HBV/HCV dual-infected patients who had received pegylated interferon treatment were recruited. The investigation outcomes included HBV DNA ≥2000 IU/mL, with or without alanine aminotransferase (ALT) ≥2-fold the upper limit of normal, and hepatitis B surface antigen (HBsAg) seroclearance.Results: Four (2.1%) patients developed early HBV reactivation before the end of treatment. Fifty (26.6%) of the remaining patients had an episode of HBV DNA ≥2000 IU/mL in a mean follow-up of 68.8 months. The risk was 4.6 per 100 person years. Only 19 (10.1%) patients developed concomitant ALT flare with oral HBV antiviral therapy; the risk was 1.7 per 100 person years. Despite HBV flare, 67 (34.9%) patients had a favorable outcome of HBsAg seroclearance. The probability was 5.7 per 100 person years. A pretreatment HBV DNA level of 300 IU/mL served as an independent predictor for all the outcomes. The combined pretreatment HBV DNA level and HCV response further enhanced the prediction of HBV flare and HBsAg seroclearance.Conclusions: A pretreatment HBV DNA level of 300 IU/mL predicts HBV flare and HBsAg seroclearance after anti-HCV therapy. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

145. Association of serial serum major histocompatibility complex class I chain‐related A measurements with hepatocellular carcinoma in chronic hepatitis C patients after viral eradication.

Author

Wang, Shu‐Chi, Huang, Ching‐I, Tsai, Pei‐Chien, Yeh, Ming‐Lun, Lin, Zu‐Yau, Chen, Shinn‐Cherng, Huang, Jee‐Fu, Chuang, Wan‐Long, Huang, Chung‐Feng, Dai, Chia‐Yen, Yu, Ming‐Lung, and Chen, Angela

Abstract

Background and Aim: Major histocompatibility complex class I chain‐related A (MICA) genetic variants and their serum levels (sMICA) were associated with the development of hepatitis C virus‐related hepatocellular carcinoma (HCC) in untreated cohorts. The dynamic changes in serial sMICA levels and their association with HCC in the post‐curative status are elusive. Methods: Single nucleotide polymorphism rs2596542 of MICA and serial sMICA levels were analyzed in chronic hepatitis C patients with a sustained virologic response after antivirals. Forty‐two patients who developed HCC and 84 age‐matched, gender‐matched, and cirrhosis propensity score‐matched non‐HCC controls were compared. Serial sMICA levels were measured within 6 months before treatment initiation (pre‐sMICA), 6 months after the end of treatment (post‐sMICA), and on the last visit before the development (or not) of HCC (last‐sMICA). Results: Cox regression analysis revealed that last‐sMICA was the only predictive factor of HCC development (hazard ratio/95% confidence interval: 2.27 (per 1 log pg/mL increase)/1.672–3.082, P < 0.001). Patients without HCC development showed a significantly reduced trend of sMICA levels during follow‐up (trend P = 0.001), which was observed only in GG genotype (trend P < 0.001) but not A allele carriers (P = 0.88). In contrast, patients with HCC showed an increased trend of sMICA levels (trend P = 0.024). However, only the GG genotype "high expressors" (trend P = 0.06) but not A allele carriers (P = 0.18) showed a correlation of substantially increased trend of sMICA levels and HCC development. Conclusions: Serial sMICA levels were associated with HCC development in SVR patients. The clinical utility of this finding is restricted to MICA rs2596542 GG genotype carriers. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

147. The role of hepatitis B and C viruses in hepatocellular carcinoma in a hepatitis B endemic area: a case-control study

Author

Chuang, Wan-Long, Chang, Wen-Yu, Lu, Sheng-Nan, Su, Wang-Pin, Lin, Zu-Yau, Chen, Shinn-Cherng, Hseih, Ming-Yuh, Wang, Liang-Yen, You, San-Lin, and Chen, Chien-Jen

Subjects
Liver cancer -- Risk factors, Hepatitis B virus -- Physiological aspects, Hepatitis C virus -- Physiological aspects, Health
Abstract

To investigate the role of hepatitis B (HBV) and C viruses (HCV) in hepatocellular carcinoma (HCC) in an HBV endemic area and elucidate the interaction of these two viruses, a case-control study of 128 patients with HCC and 384 age-matched and sex-matched control subjects was done. The positive rates of hepatitis B surface antigen (HBsAg, 77.3%, 99 of 128) and anti-HCV (19.5%, 25 of 128) in patients with HCC were significantly higher than in control subjects (P < 0.001). Both HBsAg and anti-HCV were important risk factors for HCC (relative risks, 13.96 and 27.12, respectively), and the risk for HCC was elevated significantly to 40.05 (95% confidence interval, 12.57 to 127.6) when HBsAg and anti-HCV were considered simultaneously. These results suggested that HBV and HCV were associated highly with HCC in an HBV endemic area and that these two viruses might contribute independent by synergistic effects to the pathogenesis of HCC. Cancer 1992;69:2052-2054.

Published
1992

148. Dynamics of PBMC gene expression in hepatitis C virus genotype 1-infected patients during combined peginterferon/ribavirin therapy

Author

Lu, Ming-Ying, primary, Huang, Ching-I, additional, Hsieh, Ming-Yen, additional, Hsieh, Tusty-Juan, additional, Hsi, Edward, additional, Tsai, Pei-Chien, additional, Tsai, Yi-Shan, additional, Lin, Ching-Chih, additional, Hsieh, Meng-Hsuan, additional, Liang, Po-Cheng, additional, Lin, Yi-Hung, additional, Hou, Nai-Jen, additional, Yeh, Ming-Lun, additional, Huang, Chung-Feng, additional, Lin, Zu-Yau, additional, Chen, Shinn-Cherng, additional, Huang, Jee-Fu, additional, Chuang, Wan-Long, additional, Dai, Chia-Yen, additional, and Yu, Ming-Lung, additional

Published
2016
Full Text
View/download PDF

149. The performance of acoustic radiation force impulse imaging in predicting liver fibrosis in chronic liver diseases

Author

Lin, Yi-Hung, primary, Yeh, Ming-Lun, additional, Huang, Ching-I, additional, Yang, Jeng-Fu, additional, Liang, Po-Cheng, additional, Huang, Chung-Feng, additional, Dai, Chia-Yen, additional, Lin, Zu-Yau, additional, Chen, Shinn-Cherng, additional, Huang, Jee-Fu, additional, Yu, Ming-Lung, additional, and Chuang, Wan-Long, additional

Published
2016
Full Text
View/download PDF

150. Pretreatment glucose status determines HCC development in HCV patients with mild liver disease after curative antiviral therapy

Author

Huang, Chung-Feng, primary, Yeh, Ming-Lun, additional, Huang, Cing-Yi, additional, Tsai, Pei-Chien, additional, Ko, Yu-Min, additional, Chen, Kuan-Yu, additional, Lin, Zu-Yau, additional, Chen, Shinn-Cherng, additional, Dai, Chia-Yen, additional, Chuang, Wan-Long, additional, Huang, Jee-Fu, additional, and Yu, Ming-Lung, additional

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results